TY - JOUR
T1 - The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy
T2 - a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO)
AU - Zamboglou, C.
AU - Aebersold, D. M.
AU - Albrecht, C.
AU - Boehmer, D.
AU - Ganswindt, U.
AU - Schmidt-Hegemann, N. S.
AU - Hoecht, S.
AU - Hoelscher, T.
AU - Koerber, S. A.
AU - Mueller, A. -C.
AU - Niehoff, P.
AU - Peeken, J. C.
AU - Pinkawa, M.
AU - Polat, B.
AU - Spohn, S. K. B.
AU - Wolf, F.
AU - Zips, D.
AU - Wiegel, T.
N1 - Albrecht: Nordstrahl Radiation Oncology Unit, Nürnberg North Hospital,
Prof.-Ernst-Nathan-Str. 1, 90149 Nuremberg, Germany; Wolf: Department of Radiation Oncology, Paracelsus University Hospital Salzburg, Müllner Hauptstraße 48, 5020 Salzburg, Austria
PY - 2024/8/28
Y1 - 2024/8/28
N2 - A significant number of prostate cancer patients are long-term survivors after primary definitive therapy, and the occurrence of late side effects, such as second primary cancers, has gained interest. The aim of this editorial is to discuss the most current evidence on second primary cancers based on six retrospective studies published in 2021-2024 using large data repositories not accounting for all possible confounding factors, such as smoking or pre-existing comorbidities. Overall, prostate cancer patients treated with curative radiotherapy have an increased risk (0.7-1%) of the development of second primary cancers compared to patients treated with surgery up to 25 years after treatment. However, current evidence suggests that the implementation of intensity modulated radiation therapy is not increasing the risk of second primary cancers compared to conformal 3D-planned radiotherapy. Furthermore, increasing evidence indicates that highly conformal radiotherapy techniques may not increase the probability of second primary cancers compared to radical prostatectomy. Consequently, future studies should consider the radiotherapy technique and other confounding factors to provide a more accurate estimation of the occurrence of second primary cancers.
AB - A significant number of prostate cancer patients are long-term survivors after primary definitive therapy, and the occurrence of late side effects, such as second primary cancers, has gained interest. The aim of this editorial is to discuss the most current evidence on second primary cancers based on six retrospective studies published in 2021-2024 using large data repositories not accounting for all possible confounding factors, such as smoking or pre-existing comorbidities. Overall, prostate cancer patients treated with curative radiotherapy have an increased risk (0.7-1%) of the development of second primary cancers compared to patients treated with surgery up to 25 years after treatment. However, current evidence suggests that the implementation of intensity modulated radiation therapy is not increasing the risk of second primary cancers compared to conformal 3D-planned radiotherapy. Furthermore, increasing evidence indicates that highly conformal radiotherapy techniques may not increase the probability of second primary cancers compared to radical prostatectomy. Consequently, future studies should consider the radiotherapy technique and other confounding factors to provide a more accurate estimation of the occurrence of second primary cancers.
KW - Prostate cancer
KW - Radiotherapy
KW - Second primary cancer
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001299695500001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s00066-024-02288-6
DO - 10.1007/s00066-024-02288-6
M3 - Original Article (Journal)
C2 - 39196366
SN - 0179-7158
JO - STRAHLENTHERAPIE UND ONKOLOGIE
JF - STRAHLENTHERAPIE UND ONKOLOGIE
ER -